We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
FOXC1 and SOX10 in Estrogen Receptor--Low Positive/HER2-Negative Breast Cancer: Potential Biomarkers for the Basal-like Phenotype Prediction.
- Authors
Ming Li; Shuling Zhou; Hong Lv; Mengyuan Cai; Xiaochun Wan; Hongfen Lu; Ruohong Shui; Wentao Yang
- Abstract
* Context.--Breast cancer with low (1%-10%) estrogen receptor (ER) expression (ER--low positive) constitutes a small portion of invasive breast cancers, and the treatment strategy for these tumors remains debatable. Objective.--To characterize the features and outcomes of ER--low positive patients, and clarify the clinical significance of FOXC1 and SOX10 expression in ER--low positive/HER2-negative tumors. Design.--Among 9082 patients diagnosed with primary invasive breast cancer, the clinicopathologic features of those with ER--low positive breast cancer were characterized. FOXC1 and SOX10 mRNA levels were analyzed in ER--low positive/HER2-negative cases from public data sets. The expression of FOXC1 and SOX10 in ER--low positive/HER2-negative tumors was evaluated by immunohistochemistry. Results.--The clinicopathologic study of ER--low positive tumors indicated more aggressive characteristics compared with those tumors with ER .10%, while they had more overlapping features with ER-negative tumors irrespective of the HER2 status. The intrinsic molecular subtype of ER--low positive cases with high FOXC1 and SOX10 mRNA expression was more likely to be nonluminal. Among the ER--low positive/HER2-negative tumors, 56.67% (51 of 90) and 36.67% (33 of 90) were positive for FOXC1 and SOX10, respectively, which was significantly positively correlated with CK5/6 expression. In addition, the survival analysis demonstrated no significant difference between patients who received and who did not receive endocrine therapy. Conclusions.--ER--low positive breast cancers biologically overlap more with ER-negative tumors. ER--low positive/HER2-negative cases demonstrate a high rate of FOXC1 or SOX10 expression, and these cases might be better categorized as a basal-like phenotype/subtype. FOXC1 and SOX10 testing may be used for the intrinsic phenotype prediction for ER--low positive/HER2-negative patients.
- Subjects
BREAST tumor diagnosis; PROTEIN metabolism; BREAST tumor treatment; HORMONE receptor positive breast cancer; CANCER invasiveness; PROGESTERONE receptors; IMMUNOCHEMISTRY; TUMOR markers; TRANSCRIPTION factors; GENES; MESSENGER RNA; ESTROGEN receptors; GENE expression profiling; HORMONE therapy; SURVIVAL analysis (Biometry); PHENOTYPES; EPIDERMAL growth factor receptors
- Publication
Archives of Pathology & Laboratory Medicine, 2024, Vol 148, Issue 4, p461
- ISSN
0003-9985
- Publication type
Article
- DOI
10.5858/arpa.2022-0370-OA